Zoryve 0.3% cream (roflumilast 0.3% cream) — Medica
plaque psoriasis
Preferred products
- medium-, medium-high, high-, and super-high potency topical corticosteroids including betamethasone dipropionate, augmented; clobetasol propionate; fluocinonide; halobetasol propionate; and other agents per Table 1
Initial criteria
- Patient meets BOTH of the following (A and B):
- A) age ≥ 6 years; AND
- B) ONE of the following (i or ii):
- i. Patient has tried one Step 1 Product (medium-, medium-high, high-, or super-high potency prescription topical corticosteroid); OR
- ii. Patient is treating plaque psoriasis and meets ONE of the following (a, b, or c):
- a) Patient has tried one topical vitamin D analog (e.g., calcipotriene, calcitriol, Sorilux); OR
- b) Patient has tried one combination product containing a topical vitamin D analog and topical corticosteroid (e.g., Taclonex, Enstilar, Wynzora); OR
- c) Patient is treating plaque psoriasis affecting face, eyes/eyelids, skin folds, and/or genitalia.
Approval duration
1 year